Endothelin Receptor Antagonist - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Endothelin Receptor (ET) Antagonist - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Endothelin Receptor (ET) Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Endothelin Receptor (ET) Antagonist: Overview
In mammals, the endothelin (ET) family comprises three endogenous isoforms, ET-1, ET-2 and ET-3, and the receptors that mediate their effects have been classified as the endothelin ETA and ETB receptors. Endothelin is able to activate a number of signal transduction processes including phospholipase (PL) A2, PLC and PLD, as well as cytosolic protein kinase activation.
Function - Endothelin receptors are widely expressed in all tissues, consistent with the physiological role of endothelins as ubiquitous endothelium-derived vasoactive peptides, contributing to the maintenance of vascular tone. Receptors are also localised to non-vascular structures such as epithelial cells as well as occurring in the central nervous system (CNS) on glia and neurones. Both ETA and ETB receptors are widely distributed, particularly in blood vessels. In human vessels, ETA receptors are mainly located on vascular smooth muscle cells, with ETB receptors being present on endothelial cells lining the vessel wall. ETB receptors may play a role in the release of endothelium-derived relaxing factors such as nitric oxide (NO) and prostanoids from endothelial cells where all three isoforms have a similar potency. ETA receptors present on smooth muscle cells are mainly responsible for contraction, but in animals this can vary depending on the species and vascular bed.
Endothelin Receptor (ET) Antagonists - Endothelin Receptor (ET) Antagonists (ERAs) are a type of targeted therapy used to treat people with pulmonary hypertension (PH). Targeted therapies slow the progression of PH and may even reverse some of the damage to the heart and lungs. ERAs work by reducing the amount of a substance called endothelin in the blood. Endothelin is made in the layer of cells that line the heart and blood vessels. It causes the blood vessels to constrict (become narrower). In people with PH the body produces too much endothelin. This causes the blood vessels in the lungs to become narrow, increasing the blood pressure in the pulmonary arteries. ERAs reduce the amount of endothelin in the blood, therefore limiting the harm an excess of endothelin can cause.
Endothelin Receptor (ET) Antagonist Emerging Drugs Chapters
This segment of the Endothelin Receptor (ET) Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Endothelin Receptor (ET) Antagonist Emerging Drugs
Further product details are provided in the report……..
Endothelin Receptor (ET) Antagonist: Therapeutic Assessment
This segment of the report provides insights about the different Endothelin Receptor (ET) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
Endothelin Receptor (ET) Antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Endothelin Receptor (ET) Antagonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endothelin Receptor (ET) Antagonist drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Endothelin Receptor (ET) Antagonist - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Endothelin Receptor (ET) Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Endothelin Receptor (ET) Antagonist: Overview
In mammals, the endothelin (ET) family comprises three endogenous isoforms, ET-1, ET-2 and ET-3, and the receptors that mediate their effects have been classified as the endothelin ETA and ETB receptors. Endothelin is able to activate a number of signal transduction processes including phospholipase (PL) A2, PLC and PLD, as well as cytosolic protein kinase activation.
Function - Endothelin receptors are widely expressed in all tissues, consistent with the physiological role of endothelins as ubiquitous endothelium-derived vasoactive peptides, contributing to the maintenance of vascular tone. Receptors are also localised to non-vascular structures such as epithelial cells as well as occurring in the central nervous system (CNS) on glia and neurones. Both ETA and ETB receptors are widely distributed, particularly in blood vessels. In human vessels, ETA receptors are mainly located on vascular smooth muscle cells, with ETB receptors being present on endothelial cells lining the vessel wall. ETB receptors may play a role in the release of endothelium-derived relaxing factors such as nitric oxide (NO) and prostanoids from endothelial cells where all three isoforms have a similar potency. ETA receptors present on smooth muscle cells are mainly responsible for contraction, but in animals this can vary depending on the species and vascular bed.
Endothelin Receptor (ET) Antagonists - Endothelin Receptor (ET) Antagonists (ERAs) are a type of targeted therapy used to treat people with pulmonary hypertension (PH). Targeted therapies slow the progression of PH and may even reverse some of the damage to the heart and lungs. ERAs work by reducing the amount of a substance called endothelin in the blood. Endothelin is made in the layer of cells that line the heart and blood vessels. It causes the blood vessels to constrict (become narrower). In people with PH the body produces too much endothelin. This causes the blood vessels in the lungs to become narrow, increasing the blood pressure in the pulmonary arteries. ERAs reduce the amount of endothelin in the blood, therefore limiting the harm an excess of endothelin can cause.
Endothelin Receptor (ET) Antagonist Emerging Drugs Chapters
This segment of the Endothelin Receptor (ET) Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Endothelin Receptor (ET) Antagonist Emerging Drugs
- Aprocitentan: Idorsia Pharmaceuticals
- Atrasentan: Chinook Therapeutics
- Sparsentan: Travere Therapeutics
Further product details are provided in the report……..
Endothelin Receptor (ET) Antagonist: Therapeutic Assessment
This segment of the report provides insights about the different Endothelin Receptor (ET) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Endothelin Receptor (ET) Antagonist
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Endothelin Receptor (ET) Antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Endothelin Receptor (ET) Antagonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endothelin Receptor (ET) Antagonist drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Endothelin Receptor (ET) Antagonist R&D. The therapies under development are focused on novel approaches for Endothelin Receptor (ET) Antagonist.
- Endothelin Receptor (ET) Antagonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Endothelin Receptor (ET) Antagonist drugs?
- How many Endothelin Receptor (ET) Antagonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Endothelin Receptor (ET) Antagonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Endothelin Receptor (ET) Antagonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Endothelin Receptor (ET) Antagonist and their status?
- What are the key designations that have been granted to the emerging drugs?
- Idorsia Pharmaceuticals
- Travere Therapeutics
- Chinook Therapeutics
- Actelion Pharmaceuticals
- Gmax Biopharm
- Noorik Biopharmaceuticals
- Timber Pharmaceuticals
- Spectrum Pharmaceuticals
- Pharmazz
- Aprocitentan
- Sparsentan
- Atrasentan
- Bosentan
- Macitentan
- Getagozumab
- Ambrisentan
- Sovateltide
- Sitaxentan
- BQ-123
- Clazosentan
Introduction
Executive Summary
Endothelin Receptor (ET) Antagonist: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Endothelin Receptor (ET) Antagonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Endothelin Receptor (ET) Antagonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Endothelin Receptor (ET) Antagonist Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Aprocitentan: Idorsia Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Bosentan: Actelion
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Getagozumab: Gmax Biopharm
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Endothelin Receptor (ET) Antagonist Key Companies
Endothelin Receptor (ET) Antagonist Key Products
Endothelin Receptor (ET) Antagonist- Unmet Needs
Endothelin Receptor (ET) Antagonist- Market Drivers and Barriers
Endothelin Receptor (ET) Antagonist- Future Perspectives and Conclusion
Endothelin Receptor (ET) Antagonist Analyst Views
Endothelin Receptor (ET) Antagonist Key Companies
Appendix
Executive Summary
Endothelin Receptor (ET) Antagonist: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Endothelin Receptor (ET) Antagonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Endothelin Receptor (ET) Antagonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Endothelin Receptor (ET) Antagonist Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Aprocitentan: Idorsia Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Bosentan: Actelion
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Getagozumab: Gmax Biopharm
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Endothelin Receptor (ET) Antagonist Key Companies
Endothelin Receptor (ET) Antagonist Key Products
Endothelin Receptor (ET) Antagonist- Unmet Needs
Endothelin Receptor (ET) Antagonist- Market Drivers and Barriers
Endothelin Receptor (ET) Antagonist- Future Perspectives and Conclusion
Endothelin Receptor (ET) Antagonist Analyst Views
Endothelin Receptor (ET) Antagonist Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Endothelin Receptor Antagonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Endothelin Receptor Antagonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Endothelin Receptor Antagonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Endothelin Receptor Antagonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
